Pricing models for diagnostic AI based on qualitative insights from healthcare decision makers

Why the Price Tag on Medical AI Matters

As artificial intelligence increasingly helps doctors make sense of complex lab results, scans, and patient histories, a practical question looms: who pays for these tools, and how? If pricing is confusing or unpredictable, hospitals and clinics may hesitate to use AI even when it could improve care. This article explores how health leaders think medical AI for diagnosis should be priced so it is understandable, affordable, and fair—making it more likely to reach real patients instead of remaining a flashy but underused technology.

Listening to People Who Sign Off on New Tools

The researchers interviewed 17 decision makers from hospitals, outpatient practices, laboratories, and health technology companies in Germany, Austria, and Switzerland. These were the people who help decide which digital tools to buy, how to integrate them, and how to pay for them over time. Instead of running a numerical survey, the team used in-depth conversations to uncover how these experts think about costs, budgets, and value when it comes to AI systems that support medical diagnosis. They then grouped the responses into ten recurring themes arranged under four broader areas: how prices are structured, how they fit reimbursement rules, how well they match daily work, and what they mean for long-term support and fairness.

Why Meter-Based AI Pricing Feels Wrong in Clinics

One of the clearest messages from these interviews was a strong dislike of purely technical "pay-per-use" models, such as charging by the number of data tokens, server calls, or seconds of computer time. While those measures make sense to software companies and cloud providers, they felt abstract and unmanageable to hospitals and labs that plan budgets per patient, per test, or per treatment episode. Decision makers wanted prices that they could predict from their normal workload and that felt fair in relation to the clinical benefit. They favored transparent contracts and multi-year stability over bargain prices that might fluctuate wildly with usage or obscure technical details.

Hybrid Deals and Real-World Reimbursement

Most participants gravitated toward hybrid pricing: a fixed base fee to keep the AI service running, plus a variable part tied to everyday clinical units like patients or diagnostic cases. This mix offers both planning security and a way to scale costs with actual usage. They also stressed that AI tools should plug into existing billing and reimbursement structures whenever possible. If an AI-supported diagnostic step can be billed through familiar national fee schedules, it is easier to justify and manage than a separate, stand-alone tech subscription. Many were intrigued by the idea of tying payment to better outcomes, such as more accurate diagnoses or faster treatment, but doubted that current data and legal frameworks are mature enough to reliably prove that the AI alone caused those improvements.

Fitting AI into Daily Work and Sharing the Load

Another major theme was the importance of how well AI tools fit into everyday clinical work. Decision makers were more willing to pay for systems that smoothly connect with existing lab software, electronic records, and reporting tools so staff do not need to juggle extra screens or manual steps. They saw integration, user training, and long-term support not as optional add-ons but as essential parts of the product that should be built into the price. Many also supported bundling commonly used and niche AI functions into packages. This can simplify purchasing and allow revenue from widely used features to help maintain low-volume but clinically vital functions, such as tools for rare diseases, that might otherwise be unaffordable.

Keeping Smaller Providers from Being Left Behind

Some interviewees raised worries about fairness. Smaller practices and rural labs often work with tighter margins and face more uncertainty about future funding. If AI pricing leans too heavily on usage-based fees or large upfront investments, it could widen the gap between well-funded university hospitals and smaller providers that already struggle to keep up with new technology. The authors argue that pricing models should include safeguards, such as tiered options or phased rollouts, to help under-resourced organizations take part in AI-driven improvements instead of being shut out by cost and risk.

What This Means for the Future of Medical AI

In plain terms, the study concludes that medical AI for diagnosis will only scale responsibly if its price tag is anchored in the everyday reality of healthcare. That means charging in familiar units like patients or tests, combining steady base fees with flexible usage components, making integration and support part of the deal, and linking payments to outcomes only where measurement is solid. It also means paying attention to equity so small clinics and rural hospitals are not left behind. By following these design principles, policymakers, payers, and vendors can move from experimental pilots to sustainable, widely used AI tools that improve diagnostic care without breaking the bank or deepening existing gaps.

Citation: Kirchhoff, J., Berns, F., Schieder, C. et al. Pricing models for diagnostic AI based on qualitative insights from healthcare decision makers. npj Digit. Med. 9, 231 (2026). https://doi.org/10.1038/s41746-026-02501-z

Keywords: diagnostic AI pricing, healthcare reimbursement, clinical decision support, digital health policy, equitable access